News
We send the latest information from SMC Laboratories.
Fibrosis is involved in many diseases and disease-related deaths
Today's topic is Fibrosis. We would like to discuss with you the importance of therapeutic treatments that target fibrosis. Fibrosis is involved in many diseases, so even if fibrosis is not your direct target, please read on. Fibrosis can occur in many different organs. It is caused by a disruption in the wound healing…
Introduction of bleomycin-induced SSc-ILD model
Today, we would like to introduce a more clinically correlative model in which skin and lung fibrosis develop simultaneously. Systemic scleroderma is a progressive, rare disease that causes fibrosis not only in the skin but also in tissues throughout the body, including the heart, lungs and kidneys. Pulmonary disease is a complication that has…
STAM™ mice study: demonstration of MSCs-based cell therapy study for the NASH treatment
We introduce an example of a drug evaluation study on the efficacy of cell therapy in the treatment of NASH using our STAM™ mice, model of non-alcoholic steatohepatitis (NASH). Title: Human Allogeneic Liver-Derived Progenitor Cells Significantly Improve NAFLD Activity Score and Fibrosis in Late-Stage NASH Animal Model ( Najimi et al., Cells. 2022 ) Article…
Study published in Cells. on the effects of ameliorating epigenetic modifications by ATP1A1 signalosome inhibition in the liver cancer of STAM™ mice
SMC is proud to announce that Marshall University (WV) has published the results of their study using our pre-clinical services with the STAM™ mice in Cells. Title: Normalization of the ATP1A1 Signalosome Rescinds Epigenetic Modifications and Induces Cell Autophagy in Hepatocellular Carcinoma (Rajan PK et al., Cells. 2023) Article Link ► [DOI: 10.3390/cells12192367] In this…
World COPD Day 2023 | “Breathing is Life – Act Earlier”
November 15th is World COPD Day, so why not learn more about COPD？ What is World COPD Day? World COPD Day was established by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) to raise awareness, share knowledge, and discuss ways to reduce the burden of COPD worldwide. GOLD is a global organization promoting…
【New Preclinical Data】 The effects of Il-18 inhibitor on cholangitis and liver fibtrosis in DDC-induced primary sclerosing cholangitis (PSC) model mice
We are pleased to announce that our client AprilBio Co., Ltd. (KOR) published the results of preclinical studies of IL-18 inhibitor using our DDC-induced primary sclerosing cholangitis (PSC) mouse model in the journal Biomed Pharmacother. Title: Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease (Kim DH et al., Biomed…
SMC will present study at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting
We will be presenting our study on STAM™ mice at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting to be held in Boston, MA on November 10-14, 2023. Our abstract for this presentation has been published in Hepatology (October 2023 – Volume 78 – Abstracts Supplement S1). 2348-C…
SMC will be exhibiting at The 31st Japan Digestive Disease Week (JDDW 2023)
We are pleased to announce that SMC Laboratories will be exhibiting at The 31st Japan Digestive Disease Week (JDDW 2023) from November 2th (Thu) to 5th (Sun). JDDW 2023 will be host to the 65th Annual Meeting of the Japanese Society of Gastroenterology, the 105th Congress of the Japan Gastroenterological Endoscopy Society, the 27th General…
Exciting News! Galectin Therapeutics announces positive outcome of the fourth data from its seamless adaptive Phase 2b/3 trial of Belapectin (GR-MD-02) in liver cirrhosis due to NASH/MASH
Galectin Therapeutics (GA) announced on 3rd October, 2023, positive outcome of the fourth d ata and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in liver cirrhosis due to NASH/MASH For detailed information, see the below URL. Press Release Galectin Therapeutics Reports the Positive Outcome of the…
Study published in Biomed Pharmacother. on the effects of GRP119 agonist in the treatment of NASH in STAM™ mice
SMC is proud to announce that Dong-A ST Co., Ltd. (KOR) has published the results of their study using our pre-clinical services with the STAM™ mice in Biomed Pharmacother. Title: GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling (Lee SH et al., Biomed Pharmacother., 2023) Article…